Vital Therapies has secured $22.5 million in a round of financing from 15 investors. The San Diego company will use the money to further develop its ELAD bioartificial liver, which could provide continuous liver support for patients being treated for hepatitis B, alcohol hepatitis and acute organ failure.
Calif. company developing bioartificial liver gets $22.5M boost
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan